The FDA has granted orphan drug status to eltanexor, which is being developed by Karyopharm Therapeutics. The drug is intended to treat myelodysplastic syndromes with a risk of progression to acute myeloid leukemia. Drugs with this status can receive grants from the FDA to cover clinical trial costs, tax credits and seven years of market exclusivity in the U.S. after approval.